NeoGenomics’ (NEO) Buy Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of NeoGenomics (NASDAQ:NEO) in a report released on Thursday, Marketbeat Ratings reports. They currently have a $28.00 price objective on the medical research company’s stock.

A number of other equities research analysts have also recently commented on the stock. Needham & Company LLC increased their price target on shares of NeoGenomics from $19.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, October 6th. Zacks Research downgraded shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Benchmark boosted their price objective on shares of NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Piper Sandler reaffirmed an “overweight” rating on shares of NeoGenomics in a research report on Wednesday, October 7th. Finally, Craig Hallum reiterated a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research note on Wednesday, July 29th. Eight equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, NeoGenomics presently has an average rating of “Moderate Buy” and an average price target of $20.88.

NeoGenomics Trading Down 3.1%

NeoGenomics stock opened at $17.38 on Thursday. The company has a current ratio of 3.53, a quick ratio of 3.35 and a debt-to-equity ratio of 0.47. The business’s fifty day simple moving average is $17.68 and its two-hundred day simple moving average is $12.82. NeoGenomics has a 12 month low of $7.07 and a 12 month high of $20.15. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -69.52 and a beta of 1.79.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Wednesday, October 28th. The medical research company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The firm had revenue of $209.25 million during the quarter, compared to the consensus estimate of $206.70 million. NeoGenomics had a negative return on equity of 0.99% and a negative net margin of 4.10%. The company’s revenue was up 11.3% on a year-over-year basis. During the same period last year, the company earned $0.03 earnings per share. As a group, equities analysts predict that NeoGenomics will post -0.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Root Financial Partners LLC bought a new stake in NeoGenomics in the 3rd quarter valued at $29,000. Farther Finance Advisors LLC lifted its stake in NeoGenomics by 117.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,701 shares of the medical research company’s stock worth $31,000 after purchasing an additional 917 shares in the last quarter. GAMMA Investing LLC lifted its stake in NeoGenomics by 30.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,782 shares of the medical research company’s stock worth $51,000 after purchasing an additional 644 shares in the last quarter. Allworth Financial LP lifted its stake in NeoGenomics by 110.4% in the 2nd quarter. Allworth Financial LP now owns 4,132 shares of the medical research company’s stock worth $60,000 after purchasing an additional 2,168 shares in the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in shares of NeoGenomics during the 2nd quarter valued at about $99,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics News Summary

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q3 results exceeded expectations. NeoGenomics reported third-quarter revenue of approximately $209 million, up 11.3% year over year, while earnings per share of $0.07 topped the $0.06 consensus estimate. NeoGenomics third-quarter earnings results
• Positive Sentiment: Management raised its full-year outlook. The company increased 2026 revenue guidance to $807 million-$809 million, signaling continued demand for its cancer-testing and laboratory-services business. The improved outlook was highlighted alongside the earnings beat. NeoGenomics raises 2026 guidance
• Positive Sentiment: Analyst support remains strong. BTIG Research reaffirmed its “Buy” rating and maintained a $28 price target, implying substantial upside from recent trading levels. Investors also continue to assess whether the earnings beat and higher guidance leave the stock attractively valued. BTIG Research rating
• Neutral Sentiment: CEO transition planned for January 2027. NeoGenomics disclosed that its chief executive transition is expected early next year. The change could eventually support new strategic initiatives, but investors may initially seek more clarity on succession and execution. NeoGenomics 2026 third-quarter earnings presentation
• Negative Sentiment: Profitability remains a concern. Although adjusted quarterly earnings beat estimates, the company continues to face pressure from weak reported profitability, with a negative net margin and analysts expecting a full-year loss. This may be limiting the stock’s reaction to the stronger revenue outlook.

About NeoGenomics

NeoGenomics, Inc (NASDAQ: NEO) is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company’s services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.